[1] POSTOW M A, SIDLOW R, HELLMANN M D. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. doi:  10.1056/NEJMra1703481
[2] WANG D Y, SALEM J E, COHEN J V, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728. doi:  10.1001/jamaoncol.2018.3923
[3] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南 2023[M]. 北京: 人民卫生出版社, 2023.
[4] KHUNGER M, RAKSHIT S, PASUPULETI V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials[J]. Chest, 2017, 152(2): 271-281.
[5] ZHANG M, FAN Y, NIE L G, et al. Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: a systematic review and meta-analysis[J]. Chest, 2022, 161(6): 1675-1686. doi:  10.1016/j.chest.2021.12.656
[6] DELAUNAY M, PRÉVOT G, COLLOT S, et al. Management of pulmonary toxicity associated with immune checkpoint inhibitors[J]. Eur Respir Rev, 2019, 28(154): 190012. doi:  10.1183/16000617.0012-2019
[7] KADONO T. Immune-related adverse events by immune checkpoint inhibitors[J]. Jpn J Clin Immunol, 2017, 40(2): 83-89. doi:  10.2177/jsci.40.83
[8] 王锋, 秦叔逵, 华海清, 等. 免疫检查点抑制剂相关性肺炎的临床特点及分型研究[J]. 临床肿瘤学杂志, 2021, 26(6): 541-549.
[9] 赵颖, 王锋, 宋勇, 等. 42例免疫检查点抑制剂相关肺炎的CT影像分型研究[J]. 临床肿瘤学杂志, 2023, 28(12): 1040-1045.
[10] ZHAI X Y, ZHANG J, TIAN Y R, et al. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients[J]. Cancer Biol Med, 2020, 17(3): 599-611. doi:  10.20892/j.issn.2095-3941.2020.0102
[11] GENG Y C, ZHANG Q N, FENG S W, et al. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis[J]. Cancer Med, 2021, 10(4): 1222-1239. doi:  10.1002/cam4.3718
[12] 吴建辉, 储香玲, 王李强, 等. 中国肺癌患者真实世界免疫检查点抑制剂相关性肺炎的流行病学分析[J]. 中国癌症杂志, 2022, 32(6): 469-477.
[13] HU X, RODDAY A M, GURINOVICH A, et al. Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors[J]. Immunotherapy, 2025, 17(5): 321-329. doi:  10.1080/1750743X.2025.2488728
[14] LIN X Q, DENG H Y, YANG Y L, et al. Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer[J]. Front Oncol, 2021, 11: 698832. doi:  10.3389/fonc.2021.698832
[15] SURESH K, NAIDOO J, LIN C T, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities[J]. Chest, 2018, 154(6): 1416-1423. doi:  10.1016/j.chest.2018.08.1048
[16] THOMPSON J A, SCHNEIDER B J, BRAHMER J, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241.
[17] BEATTIE J, RIZVI H, FUENTES P, et al. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade[J]. J Immunother Cancer, 2021, 9(2): e001884. doi:  10.1136/jitc-2020-001884
[18] 白春宇, 苗秋丽, 翟婧卉, 等. 替雷利珠单抗致免疫相关性肺炎文献分析与药学监护[J]. 中国医院药学杂志, 2024, 44(21): 2498-2502. doi:  10.13286/j.1001-5213.2024.21.10